NPS RADAR August 2008

Title Why read this
Dipeptidyl peptidase-4 inhibitors (‘gliptins’) for type 2 diabetes mellitus Gliptins improve glycaemic control in combination with metformin or a sulfonylurea, but their effect on diabetes-related complications and mortality is unknown.
Memantine (Ebixa) for moderately severe Alzheimer’s disease Information on use of memantine for Alzheimer's disease
Duloxetine (Cymbalta) for major depressive disorder Information on use of duloxetine for major depressive disorder
Escitalopram (Lexapro, Esipram) for generalised anxiety disorder and social anxiety disorder (social phobia) Information about use of escitalopram for generalised anxiety disorder and social anxiety disorder (social phobia)
Automatic eGFR reporting — its role in screening for kidney disease and drug-dosing decisions Information on the role of automatic eGFR (estimated glomerular filtration rate) reporting in screening for kidney disease and drug-dosing decisions
Brief item: Lercanidipine with enalapril A new fixed-dose combination preparation of lercanidipine with enalapril (Zan-Extra) was PBS listed with a restricted dose range and dose titration cautions.
Brief item: Palliative care drugs New PBS listings enable emergency use of hyoscine butylbromide injection (Buscopan) and clonazepam oral liquid (Rivotril) for palliative care patients.
Brief item: Zolpidem NPS has published a position statement on the zolpidem safety change and to describe its place in insomnia therapy.
Brief item: Rivastigmine patches Rivastigmine transdermal patches (Exelon) were PBS listed for mild to moderate Alzheimer's disease on 1 July 2008.
Brief item: Methotrexate On 1 April 2008 a smaller pack size of methotrexate tablets was PBS listed to reduce the chance of accidental overdose.
NPS RADAR August 2008 NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.